aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.25.
A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Tuesday, February 7th. Roth Capital reiterated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 3rd. Royal Bank of Canada dropped their price objective on shares of aTyr Pharma from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, March 2nd. StockNews.com lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Monday, February 20th. Finally, Roth Mkm reissued a “buy” rating and set a $9.00 target price on shares of aTyr Pharma in a research report on Monday.
aTyr Pharma Trading Down 9.2 %
LIFE stock opened at $1.93 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.55 and a current ratio of 7.55. The company’s 50-day simple moving average is $2.26 and its 200 day simple moving average is $2.52. aTyr Pharma has a 52 week low of $1.90 and a 52 week high of $6.62. The company has a market capitalization of $55.99 million, a PE ratio of -1.17 and a beta of 1.23.
Institutional Trading of aTyr Pharma
About aTyr Pharma
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.